SHR-A1921 + adebrelimab + cisplatin

SHR-A1921 + adebrelimab + cisplatin is a combination drug regimen under investigation for the treatment of solid tumors. SHR-A1921 is an antibody-drug conjugate (ADC) targeting tumor-associated antigens and delivering a topoisomerase I inhibitor payload. Adebrelimab is a fully humanized monoclonal antibody targeting programmed cell death ligand 1 (PD-L1), functioning as an immune checkpoint inhibitor. Cisplatin is a well-established platinum-based chemotherapeutic agent that induces DNA damage by forming DNA adducts, leading to apoptosis. This combination leverages direct cytotoxicity (cisplatin), targeted delivery of cytotoxic agents (SHR-A1921), and immune-mediated antitumor activity (adebrelimab). Currently, clinical trials are evaluating the efficacy and safety of these drugs in patients with advanced solid tumors or specific cancers such as platinum-resistant recurrent epithelial ovarian cancer and small cell lung cancer[1][2][5].